CAB (conformity assessment body) activity picks up in EU/US medical devices MRA (mutual recognition agreement)
This article was originally published in Clinica
Following the recent listing of the UK's SGS Yarsley as the first European conformity assessment body (CAB) authorised to conduct independent inspections on behalf of the US FDA, two more are close to being cleared. Another is not far behind, officials participating in the March MRA stakeholder teleconference heard. In all, ten EU CABs have shown interest in being part of the MRA process (see below).
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.